Advocacy intelligence hub — real-time data for patient organizations
Institute of Hematology & Blood Diseases Hospital, China — NA
Technische Universität Dresden — PHASE2
M.D. Anderson Cancer Center — PHASE1
Dana-Farber Cancer Institute — PHASE1
Fred Hutchinson Cancer Center — PHASE2
Kirsten Grønbæk — PHASE2
Istituto Clinico Humanitas — PHASE2
McMaster University — PHASE2
Ascentage Pharma Group Inc. — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Azacitidine
(AZACITIDINE)Orphan drugstandardDr. Reddy's Laboratories Inc.
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Azacitidine for injection is a pyrimidine nucleoside analog of cytidine. Azacitidine for injection is believed to exert its a...
Azacitidine
(AZACITIDINE FOR)Orphan drugstandardPilnova Pharma Inc
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Azacitidine is a pyrimidine nucleoside analog of cytidine. Azacitidine is believed to exert its antineoplastic effects by cau...
Browse all Myelodysplastic neoplasm with increased blasts news →
Naval Daver, MD, MBBS
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Timothy Olson, MD, PhD
Children's Hospital of Philadelphia
Colleen Delaney, MD
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 OLD GREENWICH, CT
Francis Giles, M.D
M.D. Anderson Cancer Center
📍 SAN ANTONIO, TX
Christine Duncan, MD
Boston Children's Hospital
Michael Pulsipher, MD, M.D
Primary Children's Hospital
📍 LOS ANGELES, CA
View all Myelodysplastic neoplasm with increased blasts specialists →